

References

Adolf GR. (1995): Human interferon omega – a review. *Mult Scler* 1(Suppl 1):S44–S47.

Akuta N, Suzuki F, Hirakawa M, et al. (2010): Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. *Hepatology* 52:421.

Andreone P, Gramenzi A, Cursaro C, et al. (2003): Interferon-alpha combined with ketoprofen as treatment of naïve patients with chronic hepatitis C: a randomized controlled trial. *J Viral Hepat* 10:306.

Antaki N, Craxi A, Kamal S et al. (2009): The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. *Liver Int* 30:342–355

Arif A, Levine RA, Sanderson SO, et al. (2003): Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. *Dig Dis Sci* 48(7):1425–1430. [PubMed: 12870807].

Arthur MJ. (1998): Fibrosis and altered matrix degradation. *Digestion* 59:376.

Bacon BR, Gordon SC, Lawitz E, et al. (2011): Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 364:1207.

Bacon BR, Shiffman ML, Lim JK, et al. (2010): Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 naïve patients: week 12 sustained virologic response rate. Presented at Digestive Disease Week, New Orleans, USA;Abstract #711b

Bain VG, Kaita KD, Yoshida EM, et al. (2006): A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. *J Hepatol* 44:671.

Battaller R, Schwabe RF, Choi YH, et al. (2003): NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. *J Clin Invest* 112:1383.

Beinhardt S, Rasoul-Rockenschaub S, Matthias Scherzer T et al. (2010): Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in patient with chronic hepatitis C. *J Hepatol*.

Benedetti A, Di Sario A, Casini A, et al. (2001): Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. *Gastroenterology* 120:545.

Benhamou Y, Afdhal NH, Nelson DR, et al. (2009): A phase III study of the safety and efficacy of viremide versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. *Hepatology* 50:717.

Bhagat, L.; Yu, D.; Trombino, A., et al. (2009): IMO-2125, a TLR9 agonist, induces Th1-type cytokines and interferons with potent anti-HCV activity in human peripheral blood mononuclear cells and plasmacytoid dendritic cells; 60th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA. Abstract 1593.

Borkham-Kamphorst E, Stoll D, Gressner AM et al. (2004): Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. *Biochem Biophys Res Commun* 321:413.

Brillanti S, Levantesi F, Masi L, et al. (2000): Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. *Hepatology* 32:630.

Buckwold VE, Wei J, Huang Z, et al. (2007): Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses. *Antiviral Res* 73(2):118–125. [PubMed: 16987555]

Caligiuri A, Bertolani C, Guerra CT, et al.(2008): Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. *Hepatology* 47:668.

Canbay A, Feldstein A, Baskin-Bey E et al. (2004): The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. *J Pharmacol Exp Ther* 308:1191.

Canbay A, Kip SN, Kahraman A et al. (2005): Apoptosis and fibrosis in non-alcoholic fatty liver disease. *Turk J Gastroenterol* 16:1.

Caronia S, Bassendine MF, Barry R et al. (2001): Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. *J Hepatol* 35:512.

Carrat F, Bani-Sadr F, Pol S, et al. (2004): Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial (RIBAVIC). *JAMA* 292:2839–48.

Chang J, Guo J, Jiang D, et al (2008): Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. *J Virol* 82(16):8215-8223.

Chen W, Liu J and Gluud C (2003): Bile acids for viral hepatitis. *Cochrane Database Syst Rev* :CD003181.

Clifford BD, Smith L, Allan C, et al. (1995): Levamisole and interferon alfa-2b as combination therapy for chronic hepatitis C: Results of a pilot study (abstract). *Gastroenterology* 108:A1051.

Connolly MK, Bedrosian AS, Mallen-St Clair J, et al. (2009): In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. *J Clin Invest* 119:3213.

Davis GL, Balart LA, Schiff ER et al.(1989):Treatment of chronic hepatitis c with recombinant interferon alfa. A multicenter randomized,controlled trial. Hepatitis interventional therapy group. *N Engl J Med.* 321(22):1501-6.

Davis GL, Nelson DR, Terrault N, et al. (2005): A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. *Liver Transpl* 11(8):941–949. [PubMed: 16035063].

De Minicis S, Candelaresi C, Marzioni M, et al. (2008): Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo. *Gut* 57:352.

Dekel R, Zvibel I, Brill S, et al. (2003): Gliotoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model. *Dig Dis Sci* 2003; 48:1642.

Demetri GD, von Mehren M, Blanke CD et al. (2002): Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. *N Engl J Med* 347:472.

Di Bisceglie AM, Shiffman ML, Everson GT et al. (2008): Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. *N Engl J Med*; 359:2429.

Di BisceglieAM, Ghalib RH, Hamzeh FM et al. (2007): Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. *J Viral Hepat.* 14:721.

Dooley S, Hamzavi J, Breitkopf K, et al. (2003): Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. *Gastroenterology* 125:178.

Durantel D (2009): Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. *Curr Opin Investig Drugs* 10(8):860–870.

Ebrahimkhani MR, Kiani S, Oakley F, et al. (2006): Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. *Gut* 55:1606.

Elmowalid GA, Qiao M, Jeong SH, et al. (2007): Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. *Proc Natl Acad Sci U S A* 104:8427.

El-Zanaty F and Way A (2009): Egypt Demographic and Health Survey, 2008. Cairo, Egypt: Ministry of Health and Population.

Esau C, Davis S, Murray S, et al (2006): miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. *Cell Metab* 3(2):87-98.

Fabris P, Tositti G, Negro F, et al. (1999): Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naïve chronic hepatitis C patients. *Aliment Pharmacol Ther* 13:1329

Fallowfield JA and Iredale JP (2004): Targeted treatments for cirrhosis. *Expert Opin Ther Targets* 8:423.

Ferenci P, Dragosics B, Dittrich H, et al. (1989): Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. *J Hepatol* 9:105.

Ferenci P, Formann E, Laferl H, et al. (2006): Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. *J Hepatol* 44:275.

Ferenci P, Laferl H, Scherzer TM et al. (2010): Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. *Gastroenterology* ;138:503–512

Ferenci P, Scherzer TM, Kerschner H, et al. (2008): Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. *Gastroenterology* 135:1561.

Fiorucci S, Antonelli E, Rizzo G, et al. (2004): The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. *Gastroenterology* 127:1497.

Flisiak R, Feinman SV, Jablkowski M, et al. (2009): The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. *Hepatology* 49:1460.

Flisiak R, Horban A, Gallay P, et al. (2008): The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfecting with hepatitis C and human immunodeficiency virus. *Hepatology* 47:817.

Folgori A, Capone S, Ruggeri L, et al. (2006): A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. *Nat Med* 12:190.

Forestier N, Reesink HW, Weegink CJ, et al. (2007): Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. *Hepatology* 46:640.

Foster GR, Zeuzem S, Andreone P, et al. (2011): Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at week 4 is not a substitute for prior null responses categorization. Presented at the 46th annual meeting of the European Association for the Study of the Liver, Berlin, Germany,

Frank C, Mohamed MK, Strickland GT et al. (2000): The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet*.355(9207):887-91.

Fried MW, Shiffman ML, Reddy KR, et al. (2002): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347:975.

Fried MW, Shiffman ML, Reddy KR, et al. (2002): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347:975.

Friedman SL (1999): Cytokines and fibrogenesis. *Semin Liver Dis* 19:129.

Friedman SL (2008): Targeting siRNA to arrest fibrosis. *Nat Biotechnol* 26:399.

Gane E, Orr D, Weilert F, et al. (2008): Phase II study of the mitochondrial antioxidant mitoquinone for hepatitis C. 43rd Annual Meeting of the European Association for the Study of the Liver. *Journal of Hepatology* 48(Suppl 2):S318.

Gane EJ, Rodriguez-Torres M, Nelson DR, et al. (2008): Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior nonresponders: interim results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. *Hepatology* 48:1024A.

Gane, E., Roberts, S., Stedman, C et al. (2009): First-in-man demonstration of potent antiviral activity with a nucleoside polymerase (R7128) and protease (R7227/ ITMN-191) inhibitor combination in HCV; safety, pharmacokinetics, and virologic results from inform-1. *J Hepatol* 50: A1046.

Gao M, Nettles RE, Belema M, et al.(2010): Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. *Nature* 465:96.

Ghany MG, Strader DB, Thomas DL, et al. (2009): Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 49:1335.

Gonzalo T, Beljaars L, van de Bovenkamp M, et al. (2007): Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. *J Pharmacol Exp Ther* 321:856.

Gosert R, Egger D, Lohmann V, et al.(2003): Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. *J Virol*;77(9):5487–5492. [PubMed: 12692249].

Hadziyannis SJ, Sette H Jr, Morgan TR, et al. (2004): Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med.* ; 140:346.

Harrison SA(2007):Small molecule and novel treatments for chronic hepatitis c virus infection . *Am J Gastroenterol.* 102:2332-2338.

Helle F and Dubuisson J (2008): Hepatitis C virus entry into host cells. *Cell Mol Life Sci* , 65:100-112.

Hennenberg M, Trebicka J, Kohistani Z, et al. (2011): Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. *Lab Invest* 91:241.

Hézode C, Forestier N, Dusheiko G, et al. (2009): Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009; 360:1839.

Hoofnagle JH and Seef LB (2006): Peginterferon and ribavirin for chronic hepatitis C. *N Engl J Med* 355:2444–2451

Idéo G, Bellobuono A, Tempini S, et al. (1999): Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. *Eur J Gastroenterol Hepatol* 11:1203.

Inagaki Y, Higashi K, Kushida M, et al. (2008): Hepatocyte growth factor suppresses profibrogenic signal transduction via nuclear export of Smad3 with galectin-7. *Gastroenterology* 134:1180.

Inagaki Y, Nemoto T, Kushida M, et al.(2003): Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. *Hepatology* ; 38:890.

Issa R, Zhou X, Trim N, et al.(2003): Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. *FASEB J* ; 17:47

Iwamoto H, Sakai H, Tada S, et al. (1999): Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. *J Lab Clin Med* 134:83.

Jacobs BP, Dennehy C, Ramirez G, et al. (2002): Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. *Am J Med* 113:506.

Jacobson IM, McHutchison JG, Dusheiko GM, et al. (2010): Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naïve patients: Final results of phase 3 ADVANCE study. *Hepatology* 52:427A.

Janssen H, de Bruijne J, Bergmann J, et al. (2009): ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, Reduced Serum Viral Load in Patients Chronically Infected with HCV. *The 60th Annual Meeting of the American Association for the Study of Liver Diseases. Hepatology* ;50(4 Suppl 1):1022A. Boston, MA.

Jensen DM, Wedemeyer H, Herring RW, et al. (2010): High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PEGIFN alfa-2a (40kd)/RBV: Planned week 12 interim analysis from the PROPEL study. *Hepatology* ; 52:360A.

Jiang D, Guo H, Xu C, et al. (2008): Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. *J Virol* ; 82:1665.

Jopling CL (2008): Regulation of hepatitis C virus by microRNA-122. *Biochem Soc Trans* ;36(Pt6):1220–1223. [PubMed: 19021529].

Julien B, Grenard P, Teixeira-Clerc F, et al. (2005): Antifibrogenic role of the cannabinoid receptor CB2 in the liver. *Gastroenterology* ; 128:742.

Kieffer TL, Sarrazin C, Miller JS, et al. (2007): Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. *Hepatology* 46:631.

Kim SY, Cho BH and Kim UH (2010): CD38-mediated Ca²⁺ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation. *J Biol Chem* 285:576.

Kim WH, Matsumoto K, Bessho K et al. (2005): Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. *Am J Pathol* 166:1017.

Korba BE, Montero AB, Farrar K, et al. (2008): Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. *Antiviral Res* 77:56.

Kwo PY, Lawitz EJ, McCone J, et al. (2010): Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. *Lancet* ; 376:705.

Lanford R, Hildebrandt-Eriksen E, Petri A, et al (2010): Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. *Science* 327(5962):198-201.

Lanford, R.E., Evans, M.J., Lohmann, V et al. (2009): The accelerating pace of HCV research: a summary of the 15th International Symposium on Hepatitis C Virus And Related Viruses. *Gastroenterology* 136: 9_16.

Langlet P, D'Heygere F, Henrion J, et al.(2009): Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients. *Aliment Pharmacol Ther* ; 30:352.

Lawitz E, Nguyen T, Younes Z et al. (2007): Clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naïve patients with HCV-1 infection: results at 24 and 48 weeks. Program and abstracts of the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL); Barcelona, Spain. Abstract 14.

Lawitz, EJ.; Zaman, A.; Muir, AJ., et al.(2008): Interim results from a phase 1b dose-escalation study of 4 weeks of peg-interferon lambda (PEG-RIL-29) treatment

in subjects with hepatitis C virus(HCV) genotype 1 with prior virologic response and relapse to peginterferon alfa and ribavirin; 59th Annual Meeting of the American Association for the Study of Liver Diseases; San Francisco, CA.

Le Pogam S, Seshaadri A, Kosaka A, et al. (2009): No evidence of R7128 drug resistance after up to 4 weeks of treatment of GT 1, 2, and 3 hepatitis C virus infected individuals. *J Hepatol.* ;50(suppl):S348.

Li J, Kuruba R, Wilson A, et al. (2010): Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. *PLoS One* 5:e13955.

Li Y, Gottwein J, Scheel T, et al (2011): MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. *Proc Natl Acad Sci U S A* 108(12):4991-4996.

Lin CC, Yeh LT, Vitarella D et al. (2003): Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. *Antivir Chem Chemother* 2003; 14:145.

Lindenbach BD, Evans MJ, Syder AJ et al. (2005): Complete replication of hepatitis C virus in cell culture. *Science* 309: 623–6.

Lohmann V, Körner F, Koch J, et al.(1999): Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285:110.

Lok A, Gardiner D, Lawitz E, et, al. (2010): Combination therapy with BMS-790052 and BMS-650032 alone or with pegylated interferon and ribavirin (pegINF/RBV) results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. *Hepatology* 52:abstract LB 8.

Lupberger J, Zeisel M, Xiao F et al. (2011): EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. *Nat Med* 17(5):589-595.

Lüscher TF and Wenzel RR (1995): Endothelin and endothelin antagonists: pharmacology and clinical implications. *Agents Actions Suppl* 45:237.

Mallet V, Gilgenkrantz H, Serpaggi J, et al. (2008): Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. *Ann Intern Med* 149:399.

Marcellin P, Fornis X, Goeser T, et al.(2011): Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. *Gastroenterology* ; 140:459.

Masson D, Koseki M, Ishibashi M, et al. (2009): Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. *Arterioscler Thromb Vasc Biol* ;29(12):2054– 2060. [PubMed: 19815817]

McCown MF, Rajyaguru S, Le Pogam S, et al. (2008): The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. *Antimicrob Agents Chemother* ; 52:1604.

McGovern BH, Abu Dayyeh BK and Chung RT (2008): Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. *Hepatology* 48:1700.

McHutchison JG, Everson GT, Gordon SC, et al. (2009): Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 360:1827.

McHutchison JG, Everson GT, Gordon SC, et al. (2009): Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 360:1827.

McHutchison JG, Lawitz EJ, Shiffman ML, et al. (2009): Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. *N Engl J Med* ;361:580–594.

McHutchison JG, Manns MP, Muir AJ, et al(2010): Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010; **362**: 1292–303.

McHutchison JG, Manns MP, Muir AJ, et al(2010): Telaprevir for previously treated chronic HCV infection. *N Engl J Med* 2010; **362**: 1292–303.

McHutchison, J.G., Patel, K., Pockros, P et al. (2006): A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. *J Hepatol* 44: 88_96.

Melhem A, Muhanna N, Bishara A, et al. (2006): Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. *J Hepatol* 45:60.

Mohamed K. Ashour, Maissa E. Elraziky, Wafaa A, et al (2011): Safety, Dosage and Efficacy of a Novel Y shaped molecule of Pegylated Interferon alpha 2a for Treatment of Chronic HCV. Accepted poster .

Moreno M, Gonzalo T, Kok RJ, et al. (2010): Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. *Hepatology* 51:942.

Muhanna N, Abu Tair L, Doron S, et al. (2011): Amelioration of hepatic fibrosis by NK cell activation. *Gut* 60:90.

Muñoz-Luque J, Ros J, Fernández-Varo G, et al. (2008): Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. *J Pharmacol Exp Ther* 324:475.

Murphy FR, Issa R, Zhou X, et al. (2002): Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. *Biol Chem* ; 277:11069.

Nahmias Y, Goldwasser J, Casali M, et al. (2008): Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. *Hepatology* 47(5):1437–1445. [PubMed: 18393287].

Neef M, Ledermann M, Saegesser H, et al. (2006): Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. *J Hepatol* ; 44:167.

Nelson DR, Ghalib RH, Sulkowski M, et al. (2009): Efficacy and safety of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a and ribavirin in previously null-responder genotype 1 HCV patients. Presented at the 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark; April 22-26, abstract #95.

Nelson DR, Lauwers GY, Lau JY et al. (2000): Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. *Gastroenterology* 118:655.

Nelson DR, Rustgi V, Balan V, et al. (2009): Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. *Clin Gastroenterol Hepatol* 7:212.

Nelson DR, Tu Z, Soldevila-Pico C, et al. (2003): Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. *Hepatology* 38:859.

Novozhenov V, Zakharova NEV, et al. (2007): Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection 58th Annual Meeting of the American Association for the Study of Liver Diseases. *J Hepatology* 46(Suppl 1):S8. Boston, MA.

Oakley F, Meso M, Iredale JP, et al. (2005): Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. *Gastroenterology* 128:108.

Oakley F, Trim N, Constandinou CM, et al. (2003): Hepatocytes express nerve growth factor during liver injury: evidence for paracrine regulation of hepatic stellate cell apoptosis. *Am J Pathol* 163:1849.

Ogawa S, Ochi T, Shimada H, et al. (2010): Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. *Hepatol Res* 40:1128.

Okuno M, Akita K, Moriwaki H, et al. (2001): Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. *Gastroenterology* 120:1784.

Paeshuyse J, Kaul A, De Clercq E, et al. (2006): The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. *Hepatology* 43:761.

Pagliaccetti NE, Eduardo R, Kleinstein SH, et al. (2008): Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. *J Biol Chem* 283(44):30079–30089. [PubMed: 18757365]

Pardo M, Castillo I, Oliva H, et al. (1997): A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. *Hepatology* 26:1318.

Parsons CJ, Bradford BU, Pan CQ, et al. (2004): Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. *Hepatology* 40:1106.

Pawlotsky JM, Chevaliez S and McHutchison JG (2007): The hepatitis C virus life cycle as a target for new antiviral therapies. *Gastroenterology* 132:1979-1998.

Pinzani M (2009): Unraveling the spider web of hepatic stellate cell apoptosis. *Gastroenterology* 136:2061.

Pockros P, Jacobson I, Boyer TD, et al. (2010): GI-5005 therapeutic vaccine plus PEG-IFN/ribavirin improves sustained virologic response versus PEG-IFN/ribavirin

in prior non-responders with genotype 1 chronic HCV infection. Hepatology 52:404A.

Pockros PJ, Jeffers L, Afdhal N, et al. (2007): Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. *Hepatology ; 45:569.*

Pockros PJ, Nelson D, Godofsky E et al. (2007): Robust synergistic antiviral effect of R1626 in combination with peginterferon alfa-2a (40KD), with or without ribavirin -- interim analysis results of phase 2a study. *Hepatology. 46:A.311A.*

Pockros PJ, Patel K, O'Brien C, et al. (2003): A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. *Hepatology 37:1368.*

Pockros PJ, Pessoa MG, Diago M, et al. (2004): Combination of levovirin (LVV) and peginterferon alfa-2a (40 kD) (Pegasys®) fails to generate a virological response comparable to ribavirin (RBV, Copegus®) and peginterferon alfa-2a (40 kD) in patients with chronic hepatitis C. *Hepatology 40(Suppl 1):391A.*

Polyak SJ, Morishima C, Shuhart MC, et al. (2007): Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. *Gastroenterology ; 132:1925.*

Poordad F, Lawitz E, Shiffman ML, et al. (2010): Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C. *Hepatology ; 52:1208.*

Poordad F, McCone J Jr, Bacon BR, et al. (2011): Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med ; 364:1195.*

Poordad F, Reddy KR and Martin P (2008): Rapid virologic response: a new milestone in the management of chronic hepatitis C. *Clin Infect Dis.46:78-84.*

Popescu CI and Dubuisson J (2010): Role of lipid metabolism in hepatitis C virus assembly and entry. *Biol Cell 102(1):63–74. [PubMed: 19857204].*

Quan C, Krajden M, Grigoriew G et al. (1993): HCV infection in patients with HIV. *Clin Infect Dis ;17:117–19.*

Raymond RS, Fallon MB and Abrams GA(1998): Oral thymic extract for chronic hepatitis C in patients previously treated with interferon. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* ; 129:797.

Reed KE and Rice CM (2000): Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. *Curr Top Microbiol Immunol* , 242:55-84.

Reesink HW, Zeuzem S, Weegink CJ, et al. (2006) :Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology* 131:997.

Reesink HW, Zeuzem S, Weegink CJ, et al. (2006) :Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. *Gastroenterology* 131:997.

Ripoll C, Groszmann R, Garcia-Tsao G, et al. (2007): Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology* 133:481.

Roberts S, Gordon A, McLean C, et al. (2007): Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. *Clin Gastroenterol Hepatol* ; 5:932.

Rockey DC and Chung JJ (1994): Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. *J Investig Med* 42:660.

Rockey DC and Chung JJ (1996): Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. *J Clin Invest* 98:1381.

Roderfeld M, Weiskirchen R, Wagner S, et al. (2006): Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. *FASEB J* 20:444.

Rossignol JF, Elfert A, and Keeffe EB (2010): Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. *J Clin Gastroenterol* 2010; 44:504.

Rossignol JF, Elfert A, El-Gohary Y et al. (2009): Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. *Gastroenterology* 2009; 136:856.

Rossignol JF, Kabil SM, El-Gohary Y, et al. (2008): Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. *Aliment Pharmacol Ther* 2008; 28:574.

Saito, T. and Gale, M. (2008): Regulation of innate immunity against hepatitis C virus infection. *Hepatology* 38: 115-122.

Sallberg M, Frelin L, Diepolder H, et al. (2009): A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. Presented at the 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark; abstract #43.

Sancho-Bru P, Bataller R, Fernandez-Varo G, et al. (2007): Bradykinin attenuates hepatocellular damage and fibrosis in rats with chronic liver injury. *Gastroenterology* 133:2019.

Santoni-Rugiu E, Preisegger KH, Kiss A, et al. (1996): Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. *Proc Natl Acad Sci U S A* 93:9577.

Sarasin-Filipowicz M, Krol J, Markiewicz I, et al (2009): Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. *Nat Med* 15(1):31-33.

Sarrazin C and Zeuzem S. (2009): Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection. *Gastroenterology* 138: 447-62.

Sarrazin C, Kieffer TL, Bartels D, et al. (2007): Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. *Gastroenterology* ; 132:1767.

Sato Y, Murase K, Kato J, et al. (2008): Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. *Nat Biotechnol* ; 26:431.

Sen, G.C. (2001): Viruses and interferons. *Annu Rev Microbiol* 55: 255-281.

Sheehy P, Mullan B, Moreau I et al. (2005): In vitro replication models for the hepatitis C virus. *J Viral Hepat.* 14:2-10.

Sherman KE, Flamm SL, Afdhal NH, et al. (2010): Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: Final results of phase 3 ILLUMINATE study. *Hepatology* 52:401A.

Sherman KE, Rouster SD, Chung RT et al. (2002): Hepatitis C virus prevalence among patients infected with human immune-deficiency virus: a cross-sectional analysis of the U.S. adult AIDS clinical trials group. *Clin Infect Dis* 34:831–73.

Shiffman ML, Ahmed A, Jacobson IM, et al. (2010): Phase 2 randomized, double-blind placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders with chronic hepatitis C genotype 1: final report. Presented at the 45th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria; April 14-18, ; abstract #1188.

Shiffman ML, Hofmann CM, Luketic VA et al. (1998): Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. *J Hepatol* 28:382.

Siller-López F, Sandoval A, Salgado S, et al. (2004): Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. *Gastroenterology* 126:1122.

Siller-López F, Sandoval A, Salgado S, et al. (2004): Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. *Gastroenterology* 126:1122.

Sulkowski M, Dieterich D, Sherman K, et al. (2011): Interim analysis of a phase 2a double-blind study of telaprevir in combination with pegIFN- α 2a and RBV in HIV/HCV co-infected patients. Presented at the 18th conference on retroviruses and opportunistic infections, Boston, MA,

Susser S, Welsch C, Wang Y, et al.(2009): Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. *Hepatology* 50:1709.

Syder A, Lee H, Zeisel M, Grove J,et al (2011): Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. *J Hepatol* 54(1):48-55.

Syed GH, Amako Y and Siddiqui A (2010): Hepatitis C virus hijacks host lipid metabolism. *Trends Endocrinol Metab* ;21(1):33–40. [PubMed: 19854061].

Tabone M, Laudi C, Delmastro B, et al. (2001): Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. *J Hepatol* 35:517.

Tada S, Iwamoto H, Nakamuta M, et al. (2001): A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats. *J Hepatol* ; 34:529.

Tai W and Chung T (2011): Investigational therapies for hepatitis C virus infection.

Taimr P, Higuchi H, Kocova E, et al(2003): Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. *Hepatology* 37:87.

Tam J, Vemuri VK, Liu J, et al. (2010): Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. *J Clin Invest* 120:2953.

Tedaldi E, Baker R, Moorman A, et al. (2003): Influence of coinfection with HCV on morbidity and mortality due to HIV infection in the era of HAART. *Clin Infect Dis* 36:363–7.

Teixeira-Clerc F, Julien B, Grenard P, et al. (2006): CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. *Nat Med* ; 12:671.

Tellinghuisen TL, Foss KL and Treadaway J (2008): Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. *PLoS Pathog* 4:e1000032.

Teuber G, Pascu M, Berg T, et al. (2003): Randomized, controlled trial with IFN- α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. *J Hepatol* 39:606.

Trappoliere M, Caligiuri A, Schmid M, et al. (2009): Silybin, a component of silymarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. *J Hepatol* 50:1102.

Trebicka J, Hennenberg M, Odenthal M, et al. (2010): Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. *J Hepatol* 53:702.

Tugues S, Fernandez-Varo G, Muñoz-Luque J, et al. (2007): Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. *Hepatology* 46:1919.

United States Food and Drug Administration. FDA approves Incivek for hepatitis C. Available from <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm>. Accessed May 23, 2011.

Valentino KL, Gutierrez M, Sanchez R, et al. (2003): First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. *Int J Clin Pharmacol Ther* 41:441.

von Wagner M, Hofmann WP, Teuber G, et al. (2008): Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. *Hepatology* 48:1404.

Wakita T, Pietschmann T, Kato T, et al. (2005): Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat Med* 11:791.

Watashi K, Hijikata M, Hosaka M, et al.(2003): Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. *Hepatology* 38:1282.

Watashi K, Ishii N, Hijikata M, et al. (2005): Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. *Mol Cell* 19:111.

Watson J (2002): Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. *Curr Opin Investig Drugs* 3:680.

Wiedmann MW and Caca K (2005): Molecularly targeted therapy for gastrointestinal cancer. *Curr Cancer Drug Targets* 5:171.

Yasuda H, Imai E, Shiota A, et al.(1996): Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. *Hepatology* 24:636.

Yoshiji H, Kuriyama S, Noguchi R, et al. (2006): Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats. *Int J Mol Med* 17:899.

Yoshiji H, Kuriyama S, Yoshii J, et al. (2002): Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. *Hepatology*; 36:850.

Yoshiji H, Noguchi R, Kuriyama S, et al. (2005): Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. *Am J Physiol Gastrointest Liver Physiol* 288:G907.

Yu JW, Wang GQ, Sun LJ et al. (2007): Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. *J Gastroenterol Hepatol* 22:832–836

Zeuzem S, Andreone P, Pol S, et al. (2011): Telaprevir for retreatment of HCV infection. *N Engl J Med* 364:2417–28.

Zeuzem S, Hultcrantz R, Bourliere M, et al. (2004): Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. *J Hepatol* ; 40:993 .

Zeuzem S, Sulkowski MS, Lawitz EJ, et al. (2010): Albinterferon Alfa-2b was not inferior to pegylated interferon- α in a randomized trial of patients with chronic hepatitis C virus genotype 1. *Gastroenterology* 139:1257.

Zeuzem S, Sulkowski MS, Zoulim F, et al. (2010): Long-term follow-up of patients with chronic hepatitis C treated with tepalprevir in combination with peginterferon alfa-2a and ribavirin: Interim analysis of the EXTEND study. *Hepatology* 52:436A.

Zhang Y and Edwards PA (2008): FXR signaling in metabolic disease. *FEBS Lett* ; 582:10.

Zheng S and Chen A (2007): Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of peroxisome proliferator-activated receptor-gamma in rat hepatic stellate cells. *Am J Physiol Gastrointest Liver Physiol* 292:G113.

Zhu, H., Dong, H., Eksioglu, E et al. (2007): Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. *Gastroenterology* 133: 1649_1659.